Evidence map›Paper›PMID 40331629›Full record

ArticleNucleic acids research2025

The structure of the Vibrio natriegens 70S ribosome in complex with the proline-rich antimicrobial peptide Bac5(1-17).

Karoline Raulf, Timm O Koller, Bertrand Beckert, Alexander Lepak, Martino Morici, Mario Mardirossian, Marco Scocchi, Gert Bange, Daniel N Wilson

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Karoline RaulfInstitute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg 20146, Germany.
Timm O KollerInstitute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg 20146, Germany.
Bertrand BeckertInstitute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg 20146, Germany.
Alexander LepakCenter for Synthetic Microbiology (SYNMIKRO) and Department of Chemistry, University of Marburg, Karl-von-Frisch-Strasse 14, 35043 Marburg, Germany.
Martino MoriciInstitute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg 20146, Germany.
Mario MardirossianDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Marco ScocchiDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Gert BangeCenter for Synthetic Microbiology (SYNMIKRO) and Department of Chemistry, University of Marburg, Karl-von-Frisch-Strasse 14, 35043 Marburg, Germany.ORCID 0000-0002-7826-0932
Daniel N WilsonInstitute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg 20146, Germany.ORCID 0000-0003-3816-3828

Funding

Deutsche Forschungsgemeinschaft SPP 1879Horizon 2020 LM2018127University of Hamburg
6 · The paper itself

Abstract

Proline-rich antimicrobial peptides (PrAMPs) are produced as part of the innate immune response of animals, insects, and plants. The well-characterized mammalian PrAMP bactenecin-5 (Bac5) has been shown to help fight bacterial infection by binding to the bacterial ribosome and inhibiting protein synthesis. In the absence of Bac5-ribosome structures, the binding mode of Bac5 and exact mechanism of action has remained unclear. Here, we present a cryo-electron microscopy structure of Bac5 in complex with the 70S ribosome from the Gram-negative marine bacterium Vibrio natriegens. The structure shows that, despite sequence similarity to Bac7 and other type I PrAMPs, Bac5 displays a completely distinct mode of interaction with the ribosomal exit tunnel. Bac5 overlaps with the binding site of both A- and P-site transfer RNAs bound at the peptidyltransferase center, suggesting that this type I PrAMP can interfere with late stages of translation initiation as well as early stages of elongation. Collectively, our study presents a ribosome structure from V. natriegens, a fast-growing bacterium that has interesting biotechnological and synthetic biology applications, as well as providing additional insights into the diverse binding modes that type I PrAMPs can utilize to inhibit protein synthesis.

Indexed as

Antimicrobial PeptidesPeptides, CyclicRibosomesVibrioBinding SitesCryoelectron MicroscopyModels, MolecularProlineProtein BindingProtein BiosynthesisAntimicrobial PeptidesbactenecinPeptides, CyclicProline

Identifiers

PMID40331629
PMCPMC12056610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.